Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.89Last Year’s EPS
-0.69Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -0.74%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical progress and strategic initiatives, such as the advancement of STAT6 and TYK2 programs and the expansion of collaboration with Sanofi, which supports a positive outlook. However, increased operational costs and limited revenue diversification present challenges.Company Guidance
During the Kymera Therapeutics Fourth Quarter 2024 Results Call, the company outlined several key performance metrics and plans for the upcoming year. The Chief Executive Officer, Nello Mainolfi, highlighted the completion of IND-enabling studies for STAT6 (KT-621), the initiation of a Phase I study, and plans to complete the final MAD cohorts. The company also named KT-295 as a development candidate for TYK2, with IND-enabling studies underway. In collaboration with Sanofi, Kymera is progressing two Phase IIb studies for IRAK4 in hidradenitis suppurativa and atopic dermatitis, which have been expanded to accelerate timelines towards pivotal trials. Financially, the company reported $7.4 million in revenue for Q4 2024, all from its Sanofi collaboration, and ended the year with $851 million in cash, providing a runway into mid-2027. For 2025, Kymera plans to report Phase I data for KT-621 in June and initiate two Phase 2b studies, with a goal of delivering at least one new IND per year.Clinical Progress in STAT6 and TYK2 Programs
Kymera completed IND-enabling studies for KT-621, initiated a Phase I study, and advanced KT-295 with plans for clinical data readouts in 2025. This positions the company as a leader in STAT6 targeted therapy development.
Sanofi Collaboration Expansion
Sanofi expanded the Phase IIb studies in hidradenitis suppurativa and atopic dermatitis to accelerate development timelines towards pivotal trials, indicating strong progress and partnership value.
Strong Financial Position
Kymera ended 2024 with a cash balance of $851 million, providing runway into mid-2027 to support multiple data readouts, including significant Phase II trials.
Introduction of New Immunology Target
Kymera plans to unveil a new immunology program targeting an undrugged transcription factor, expected to be a first-in-class agent for autoimmune diseases.
---
KYMR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KYMR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $35.36 | $30.25 | -14.45% |
| Oct 31, 2024 | $47.67 | $46.17 | -3.15% |
| Aug 07, 2024 | $41.42 | $40.31 | -2.68% |
| May 02, 2024 | $36.24 | $36.30 | +0.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kymera Therapeutics (KYMR) report earnings?
Kymera Therapeutics (KYMR) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Kymera Therapeutics (KYMR) earnings time?
Kymera Therapeutics (KYMR) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KYMR EPS forecast?
KYMR EPS forecast for the fiscal quarter 2025 (Q1) is -0.89.
---